



Five years on, Covid-19 remains NZ's most important infectious disease - it still demands a strong response

26 February 2025

Michael Baker, Amanda Kvalsvig, John Donne Potter, Matire Harwood, Nick Wilson

Summary

This week marks five years since Covid-19 was first reported in Aotearoa New Zealand (NZ). The successful elimination strategy kept case numbers low for the first two years, followed by three years of widespread transmission with mitigation measures aiming to reduce the harms to population health. Although hospitalisations and deaths have declined substantially, Māori and Pacific peoples face disproportionate impacts, and Long Covid is an increasing health and economic burden.

Covid-19 remains our most important infectious disease and demands a proportionate response. We need an evidence-informed national plan, ongoing surveillance, regular vaccinations, and improved public health and social measures such as better indoor air quality, free RAT testing, and mask-wearing in high-risk indoor settings. Addressing hospital-acquired Covid-19 infections and Long Covid are crucial. NZ should enhance its pandemic preparedness by implementing recommendations from the Covid-19 Royal Commission of Inquiry, strengthening cooperation with Australia, and countering misinformation.

This Friday, February 28, marks five years since Covid-19 was [first reported](#) in Aotearoa New Zealand. At a population level, it remains our most harmful infectious disease, with thousands of hospitalisations and 664 deaths last year.


Understandably perhaps, many people want to move on from the early pandemic years, and there is a temptation to minimise Covid-19's threat now the emergency response has passed.

But it deserves a proportionate response that draws on the rich evidence we now have of how to minimise the harms of respiratory infections and the health and economic benefits that come from managing them well.

The epidemiology of the SARS-CoV-2 virus continues to change. [Hospitalisations provide the most consistent measure](#) of incidence trends. Wastewater testing shows [similar successive waves of infection](#).

The past five years divide into a successful elimination response¹ from March 2020 to late 2021 and a mitigation period from February 2022 onwards.

NZ Covid-19 hospitalisations per 100,000 populations, rolling 7-day average



Source: Te Whatu Ora

The mitigation phase, which has now lasted three years, has been driven by Omicron variants of SARS-CoV-2, with seven waves of generally decreasing size (see graph above).

Total hospitalisations have dropped from a peak of more than 22,000 in 2022 to about 9,000 in 2024 (a 60% decline). Deaths attributed to Covid-19 have also decreased from 2,757 in 2022 to 664 in 2024 (a 76% decline). These drops are likely to reflect changes in both the virus and population immunity² arising from vaccination and infection.

The timing and size of Covid-19 waves remain unpredictable. They are [not following a seasonal pattern](#) like influenza. Only two of the seven Omicron waves peaked in the flu season (see graph above).

Although further declines are likely, it is possible a large-scale change in the virus could emerge – as we've seen with Delta and Omicron variants – and reverse this pattern. We still need to plan for the possibility of severe future variants as well as for other types of pandemics [that might be becoming more likely](#).

Health and economic impacts of Long Covid

Despite a favourable downward trend, deaths and hospitalisations from Covid-19 are still higher than those estimated for influenza, which is probably our next most burdensome infectious disease.

It is also a major cause of health inequities³ with significantly worse infection outcomes for Māori and Pacific peoples.

Continuing high rates of repeat infections are also driving Long Covid-19, with the [risk estimated at 4-14% per infection](#).⁴ Long Covid occurs with infections of all intensities,⁵ with both initial infection and reinfections.⁶

Consequently, the prevalence of Long Covid is likely to increase over time,⁷ with substantial health and economic consequences.⁸

How to respond to the ongoing pandemic

We know what works to reduce the harms from Covid-19. Above all, we need an evidence-informed national plan, clear communication, engagement with key partners (including the health sector, public and Māori), resources and implementation. Key elements include:

1. Continuing and enhancing highly effective Covid-19 surveillance

Surveillance systems include use of wastewater testing and whole-genome sequencing which guide our response. We need to add a focus on hospital-acquired Covid-19 which is an important source of infections and deaths, estimated to have caused about [14% of Covid-19 deaths in New South Wales in 2023](#), which would represent about 150 deaths that year in New Zealand.

2. Promoting regular repeat vaccinations

The currently available Pfizer JN.1 vaccine provides a reasonable match with the circulating strain of the virus. This vaccine is [very safe](#)⁹ and effective at reducing many adverse effects of infection, including Long Covid, but [requires regular additional doses](#)¹⁰ for all age groups to maintain effectiveness.

3. Using public health and social measures to reduce infections

These measures include improving indoor air quality and promoting testing and self-isolation for those with respiratory symptoms. Reintroducing free RAT tests and sick-leave support would help.

Wearing respirator masks (for example, N95) is highly effective,¹¹ particularly in confined indoor environments such as public transport. Given the severe effects of hospital-acquired Covid-19, health settings need particular attention. Evidence supports the effectiveness and value of admission testing of patients and staff wearing N95 masks.¹²

4. Taking specific measures to reduce and manage Long Covid

This means active steps to reduce both the incidence of infection (with public health and social measures) and the severity and duration of illness (with vaccination and antivirals).¹³ New Zealand needs to offer more than a single additional dose for younger age groups to improve their protection from Long Covid.

5. Updating and implementing our pandemic preparedness and response plan

The Royal Commission of Inquiry into Covid-19 delivered a set of [recommendations based on the pandemic experience](#).¹⁴ Now is the time to implement them.

Our capacity could be supported through a [New Zealand Centre for Disease Control](#) and a [pandemic cooperation agreement with Australia](#).¹⁵ Developing these pandemic

capabilities would help to minimise Covid-19 and other respiratory infections,¹⁶ including influenza.

All of these measures would be supported by a strong, systematic response to the corrosive effects of misinformation and disinformation.¹⁷

The past five years have taught us a great deal about pandemic diseases and how to manage them. A key lesson from New Zealand's highly successful early elimination response was the importance of good evidence-informed leadership and a cohesive plan.¹⁸

Such leadership is still needed now to mitigate the harm from Covid-19 which remains an ongoing threat to individual and societal wellbeing.

What this Briefing adds

- Covid-19 first arrived in NZ in Feb 2020, but infections were kept at low levels for two years with a successful elimination strategy, allowing time for high vaccine coverage and other protective measures
- During the following three years NZ has experienced widespread infection with Omicron subvariants resulting in seven waves of infection to date and a high year-round baseline
- The impact of the pandemic, as measured by hospitalisations and deaths, has declined but the repeated infections are likely to increase the proportion of the population living with Long Covid

Implications for policy and practice

- Continue and refine current Covid surveillance and add systems for hospital-acquired Covid-19 and Long Covid
- Promote regular additional doses of vaccine for all age groups to maintain effectiveness including some protection against Long Covid
- Support public health and social measures to reduce infections, including: improving indoor air quality (especially in schools), promoting testing and self-isolation for those with respiratory symptoms (eg, reintroduction of free RAT tests), and promoting use of respirator (eg, N95) masks on public transport and in health care settings
- Immediately update and implement our pandemic preparedness and response plan using findings from the Royal Commission of Inquiry into Covid-19

This article is republished and adapted from [The Conversation](#) under a Creative Commons license. Read the [original article](#).

We encourage readers to make [submissions on Phase Two](#) of the *Royal Commission of Inquiry into COVID-19 Lessons Learned*. These are due by 27 April 2025.

As noted in this Briefing article, pandemic risk is likely increasing. It is therefore crucial to implement the comprehensive recommendations of the Phase One Report without delay, rather than waiting for the Phase Two Report, which is not due until early 2026.

Authors details

[Prof Michael Baker](#), Director, Public Health Communication Centre, and Department of Public Health, Ōtākou Whakaihu Waka, Pōneke - University of Otago, Wellington

[Assoc Prof Amanda Kvalsvig](#), Research Associate Professor of Public Health, University of Otago

[Prof John Potter](#), Professor of Public Health, Centre for Public Health Research, Te Kunenga ki Pūrehuroa - Massey University, Wellington

[Assoc Prof Matire Harwood](#), Associate Professor of Health Science, University of Auckland - Waipapa Taumata Rau

[Prof Nick Wilson](#), Co-Director, Public Health Communication Centre, and Department of Public Health, Ōtākou Whakaihu Waka, Pōneke - University of Otago, Wellington

References

1. Baker MG, Kvalsvig A, Plank MJ, Geoghegan JL, Wall T, Tukuitonga C, et al. Continued mitigation needed to minimise the high health burden from COVID-19 in Aotearoa New Zealand. *New Zealand Medical Journal*. 2023;136(1583):67-91.
<https://doi.org/10.26635/6965.6247>
2. Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. Differential protection against SARS-CoV-2 reinfection pre- and post-Omicron. *Nature*. 2025.
<https://doi.org/10.1038/s41586-024-08511-9>
3. Curtis E, Jaung R, Paine S-J, McLeod M, Tamatea J, Atkinson J, et al. Examining the impact of COVID-19 on Māori:non-Māori health inequities in Aotearoa, New Zealand: an observational study protocol. *BMJ Open*. 2024;14(3):e083564.
<https://bmjopen.bmj.com/content/bmjopen/14/3/e083564.full.pdf>
4. Kvalsvig A, Brooks A, Potter J, Jeffreys M, Bennett J, Davies-Payne D, Kennedy J, Sika-Paotonu D, Timu-Parata C, Crossan J, Hume C, Russell L, Lorgelly P, Baker M. Long Covid in Aotearoa NZ: Risk assessment and preventive action urgently needed. *Public Health Expert Briefing* (26 March 2024).
<https://www.phcc.org.nz/briefing/long-covid-aotearoa-nz-risk-assessment-and-preventive-action-urgently-needed>
5. Ely WE, Brown LM, Fineberg HV. Long Covid Defined. *The New England Journal of Medicine*. 2024;391(18):1746 - 53.
<https://www.nejm.org/doi/full/10.1056/NEJMs2408466>
6. Qin S, Zhang Y, Li Y, Huang L, Yang T, Si J, et al. Long COVID facts and findings: a large-scale online survey in 74,075 Chinese participants. *The Lancet Regional Health - Western Pacific*. 2024;52:101218.

[https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065\(24\)00212-8/fulltext](https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(24)00212-8/fulltext)

7. Bartsch SM, Chin KL, Strych U, John DC, Shah TD, Bottazzi ME, et al. The Current and Future Burden of Long COVID in the United States (U.S.). *The Journal of Infectious Diseases*. 2025. <https://doi.org/10.1093/infdis/jiaf030>
8. Kvalsvig A, Kerr J, Lorgelly P, Wilson N, Baker M. Long Covid: High economic burden justifies further preventive efforts. *Public Health Expert Briefing*. (9 September 2024). <https://www.phcc.org.nz/briefing/long-covid-high-economic-burden-justifies-further-preventive-efforts>
9. Petousis-Harris H, Paynter J, Chisholm H, Batty K, Baker M. Robust vaccine surveillance shows safety – we need to communicate this better. *Public Health Expert Briefing* (19 September 2024). <https://www.phcc.org.nz/briefing/robust-vaccine-surveillance-shows-safety-we-need-to-communicate-better>
10. Potter JD, Baker M, Ingram J. Covid-19 vaccines still protect us: How do we get the best out of them? *Public Health Expert Briefing*. (1 August 2024). <https://www.phcc.org.nz/briefing/covid-19-vaccines-still-protect-us-how-do-we-get-the-best-out-them>
11. Greenhalgh T, MacIntyre CR, Baker Michael G, Bhattacharjee S, Chughtai Abrar A, Fisman D, et al. Masks and respirators for prevention of respiratory infections: a state of the science review. *Clin Microbiol Rev*. 2024;37(2):e00124-23. <https://doi.org/10.1128/cmr.00124-23>
12. McAndrew F, Abey Suriya RG, Sacks-Davis R, Sammann M, Lister DM, West D, et al. Admission screening testing of patients and staff N95 respirators are cost-effective in reducing COVID-19 hospital-acquired infections. *J Hosp Infect*. 2024;152:81-92. <https://doi.org/10.1016/j.jhin.2024.06.015>
13. Sun G, Lin K, Ai J, Zhang W. The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2024;30(12):1505-13. <https://doi.org/10.1016/j.cmi.2024.07.006>
14. Baker M, Kvalsvig A, Tukuitonga C, Wilson N. The Covid inquiry report is an excellent guide to preparing for the next pandemic – health cuts put that at risk. *Public Health Expert Briefing*. (5 December 2024). <https://www.phcc.org.nz/briefing/covid-inquiry-report-excellent-guide-preparing-next-pandemic-health-cuts-put-risk>
15. Baker M, Crump J, Kvalsvig A, Geohegan J, Tukuitonga C, Brewerton M, Kerr J, Wilson N. Why we need an Aotearoa Centre for Disease Control (CDC). *Public Health Expert Briefing* (16 November 2023). <https://www.phcc.org.nz/briefing/why-we-need-aotearoa-centre-disease-control-cdc>
16. Kvalsvig A, Barnard LT, Summers J, Baker MG. Integrated Prevention and Control of Seasonal Respiratory Infections in Aotearoa New Zealand: next steps for transformative change. *Policy Quarterly*. 2022;18(1):44-51. <https://ojs.victoria.ac.nz/pq/article/view/7500>
17. Kisa S, Kisa A. A Comprehensive Analysis of COVID-19 Misinformation, Public Health Impacts, and Communication Strategies: Scoping Review. *J Med Internet Res*. 2024;26:e56931. <https://doi.org/10.2196/56931>
18. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases. *BMJ*. 2020;371:m4907. <https://doi.org/10.1136/bmj.m4907>



Source URL:

<https://www.phcc.org.nz/briefing/five-years-covid-19-remains-nzs-most-important-infectious-disease-it-still-demands-strong>